Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
NEW YORK, March 31, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Stemline Therapeutics, Inc. (NASDAQ:STML) securities (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/stemline-therapeutics. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
If you suffered a loss in Stemline you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/stemline-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
